Literature DB >> 30037178

Robot-assisted extended lymphadenectomy in prostate cancer.

Stavros I Tyritzis1,2, Nikolaos Kalampokis3, Nikolaos Grivas3,4, Henk van der Poel4, N Peter Wiklund5.   

Abstract

INTRODUCTION: The extent of lymph node dissection (LND) and its potential survival benefit are still a matter of debate. Aim of our review was to summarize the latest literature data regarding the surgical templates, the potential oncological benefits, the functional outcomes and the complications of extended lymph node dissection (eLND) during robot-assisted radical prostatectomy (RARP). EVIDENCE ACQUISITION: We systematically reviewed all relevant studies using PubMed, MEDLINE, Embase, American Urological Association (AUA), European Society of Medical Oncology (ESMO) and European Association of Urology (EAU) guidelines. EVIDENCE SYNTHESIS: A narrative synthesis of all relevant publications on surgical templates, complications, oncological and functional outcomes of robot assisted eLND was undertaken.
CONCLUSIONS: A great deal of evidence supports that an extended template of LND is not only technically feasible but also safe in the context of RARP. It is really promising that in the era of minimally invasive surgery, parameters like the lymph node yield and the detection rates of positive lymph nodes during LND have become highly comparable with open series. The extended approach has already proved its benefits in terms of proper patient staging but more studies are needed with regard to functional outcomes and oncological benefits of this procedure.

Entities:  

Mesh:

Year:  2018        PMID: 30037178     DOI: 10.23736/S0026-4733.18.07780-5

Source DB:  PubMed          Journal:  Minerva Chir        ISSN: 0026-4733            Impact factor:   1.000


  1 in total

1.  Development of a novel nomogram to identify the candidate to extended pelvic lymph node dissection in patients who underwent mpMRI and target biopsy only.

Authors:  Cristian Fiori; Enrico Checcucci; Ilaria Stura; Daniele Amparore; Sabrina De Cillis; Alberto Piana; Stefano Granato; Gabriele Volpi; Michele Sica; Federico Piramide; Paolo Verri; Matteo Manfredi; Stefano De Luca; Riccardo Autorino; Giuseppe Migliaretti; Francesco Porpiglia
Journal:  Prostate Cancer Prostatic Dis       Date:  2022-06-24       Impact factor: 5.554

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.